Category - Developments

Developments

OIO grants HEALWELL regulatory approval to acquire Orion Health

HEALWELL AI (TSX:AIDX; QTCQX:HWAIF) has announced that New Zealand’s Overseas Investment Office (OIO) has granted consent for the company to acquire all ordinary shares of Orion Health, based in Auckland, New Zealand...

February 10, 2025

Developments

Medincell reports completion of Phase 3 trial of olanzapine LAI in schizophrenia

Medincell (EPA:MEDCL) has announced the completion of SOLARIS, its Phase 3 trial of olanzapine LAI in patients with schizophrenia, conducted by Teva Pharmaceuticals (NYSE:TEVA). Medicell reports that it will receive a...

February 10, 2025

Developments

FDA fast tracks Biodexa’s eRapa in FAP

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA...

February 10, 2025

Developments

Ekso Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has named National Seating & Mobility (NSM), a leading provider of complex rehabilitation technology (CRT), mobility and accessibility solutions, as the exclusive Ekso...

February 10, 2025

Developments

Firefly congratulates company advisor, Dr. Christopher Wilson, on UW Faculty of Engineering Award for his work on superconducting quantum electronics

Firefly Neuroscience (NASDAQ:AIFF) has announced that Christopher Wilson, Ph.D., has been honored with the prestigious UW Faculty of Engineering Award by the University of Waterloo (UW) for his significant contributions...

February 7, 2025

Developments

Fennec unveils PEDMARQSI in Germany for cisplatin-induced hearing loss in children

Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced the commercial launch of PEDMARQSI sodium thiosulfate injection in Germany by Norgine Pharmaceuticals. The treatment is designed to prevent ototoxicity (permanent...

February 7, 2025

Developments

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo

AIM ImmunoTech (NYSE:AIM) has announced plans for a follow-up clinical study to evaluate the potential avian influenza combination therapy of its Ampligen with Astra Zeneca’s (NASDAQ: AZN) FluMist. According to AIM, the...

February 7, 2025

Developments

Lively X discussion about the clinical potential of Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgeries helps drive stock

Perimeter Medical Imaging AI’s (TSX-V:PINK; OTC:PYNKF) ultra-high-res imaging tool for use during breast cancer surgeries was highlighted in a conversation today on X driven by renowned Silicon Valley venture...

February 4, 2025

Developments

Pyxis initiates new combination trial; expands existing monotherapy trial

Pyxis Oncology (NASDAQ:PYXS) has announced the initiation of a Phase 1/2 combination trial of its PYX-201 in conjunction with Merk’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of multiple...

February 4, 2025

Developments

uniQure completes enrollment for Phase 1/2a trial of gene therapy in Fabry disease

uniQure (NASDAQ:QURE) has announced the completion of enrollment for its Phase 1/2a trial of AMT-191 in patients with Fabry disease. The company also reports receiving a favorable recommendation from the Independent...

February 3, 2025

Category - Developments

Subscribe